Published in Women's Health Weekly, February 7th, 2008
The revised labeling includes two new additional estimates of relative risk (odds ratios) for venous thromboembolic events (VTE) of 1.1 (indicating no increase in risk) and 2.0 (indicating an approximate doubling of risk) in women using ORTHO EVRA compared to women using birth control pills. The previous labeling reported two estimates of relative risk for VTE of 0.9 (indicating no increase in risk) and 2.4 (indicating an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly